Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

Part of paid clinical trials in Orlando, Florida.

Sponsor
AstraZeneca
Study ID
NCT07754331
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Kidney Failure

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate the effect of HD on single oral dose PK, safety, and tolerability of balcinrenone/dapagliflozin to male and female participants with kidney failure on intermittent HD.

Key Dates

First listed
Aug 10, 2026
Start date
Aug 5, 2026
Status verified
Aug 2026
Primary completion
Dec 2, 2026
Completion
Dec 2, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Other: Sequence AB
    Two hours after completion of a breakfast meal on Day 1, a single oral balcinrenone/dapagliflozin dose will be administered. A 4-hour HD session will start 1.5 hours after dose administration.
  • Other: Sequence BA
    One hour after completion of a breakfast meal on Day 1, a 4-hour HD session will start. One hour after completion of the HD session a single oral balcinrenone/dapagliflozin dose will be administered.

Primary Outcome Measure

PK parameters AUCinf [ Time Frame: Day 1 to 3 for each treatment period (each treatment period is 4 days) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteOrlandoFlorida32809-

Related Studies